Phase I and pharmacological studies of pentamethylmelamine administered by 24-hour intravenous infusion

E. S. Casper, Richard J. Gralla, G. R. Lynch

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

A Phase I study of pentamethylmelamine (PMM) was conducted, administering the drug as a 24-hr i.v. infusion once weekly for 3 weeks. Doses ranged from 80 to 3000 mg/sq m/week. Twenty-six evaluable patients received a total of 30 courses of PMM. The median performance status of the courses of PMM. The median performance status of the patients was 60% (range, 40 to 90%), and the median age wa 58 years (range, 43 to 72 years). The highest tolerated dose was 2000 mg/sq m/ week. Nausea and vomiting were the dose-limiting toxicities; myelosuppression was neither consistent nor severe. One objective response lasting 10 months was noted in a patient with renal cancer. Pharmacokinetic studies using [ring-14C]PMM demonstrated a postinfusion half-life of 1:4C of approximately 12 hr, with the majority of the radiolabel excreted in the urine. PMM was introduced as a parenteral form of hexamethylmelamine. The present schedule does not permit adminstration of PMM in a dose not apear to offer an advantage over the p.o. use of the parent compound.

Original languageEnglish (US)
Pages (from-to)1402-1406
Number of pages5
JournalCancer Research
Volume41
Issue number4
StatePublished - 1981
Externally publishedYes

Fingerprint

Intravenous Infusions
Pharmacology
Altretamine
Kidney Neoplasms
Nausea
Vomiting
Half-Life
pentamethylmelamine
Appointments and Schedules
Pharmacokinetics
Urine
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase I and pharmacological studies of pentamethylmelamine administered by 24-hour intravenous infusion. / Casper, E. S.; Gralla, Richard J.; Lynch, G. R.

In: Cancer Research, Vol. 41, No. 4, 1981, p. 1402-1406.

Research output: Contribution to journalArticle

@article{afd90b7b3af448ae9a12eedcbcd6abcb,
title = "Phase I and pharmacological studies of pentamethylmelamine administered by 24-hour intravenous infusion",
abstract = "A Phase I study of pentamethylmelamine (PMM) was conducted, administering the drug as a 24-hr i.v. infusion once weekly for 3 weeks. Doses ranged from 80 to 3000 mg/sq m/week. Twenty-six evaluable patients received a total of 30 courses of PMM. The median performance status of the courses of PMM. The median performance status of the patients was 60{\%} (range, 40 to 90{\%}), and the median age wa 58 years (range, 43 to 72 years). The highest tolerated dose was 2000 mg/sq m/ week. Nausea and vomiting were the dose-limiting toxicities; myelosuppression was neither consistent nor severe. One objective response lasting 10 months was noted in a patient with renal cancer. Pharmacokinetic studies using [ring-14C]PMM demonstrated a postinfusion half-life of 1:4C of approximately 12 hr, with the majority of the radiolabel excreted in the urine. PMM was introduced as a parenteral form of hexamethylmelamine. The present schedule does not permit adminstration of PMM in a dose not apear to offer an advantage over the p.o. use of the parent compound.",
author = "Casper, {E. S.} and Gralla, {Richard J.} and Lynch, {G. R.}",
year = "1981",
language = "English (US)",
volume = "41",
pages = "1402--1406",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Phase I and pharmacological studies of pentamethylmelamine administered by 24-hour intravenous infusion

AU - Casper, E. S.

AU - Gralla, Richard J.

AU - Lynch, G. R.

PY - 1981

Y1 - 1981

N2 - A Phase I study of pentamethylmelamine (PMM) was conducted, administering the drug as a 24-hr i.v. infusion once weekly for 3 weeks. Doses ranged from 80 to 3000 mg/sq m/week. Twenty-six evaluable patients received a total of 30 courses of PMM. The median performance status of the courses of PMM. The median performance status of the patients was 60% (range, 40 to 90%), and the median age wa 58 years (range, 43 to 72 years). The highest tolerated dose was 2000 mg/sq m/ week. Nausea and vomiting were the dose-limiting toxicities; myelosuppression was neither consistent nor severe. One objective response lasting 10 months was noted in a patient with renal cancer. Pharmacokinetic studies using [ring-14C]PMM demonstrated a postinfusion half-life of 1:4C of approximately 12 hr, with the majority of the radiolabel excreted in the urine. PMM was introduced as a parenteral form of hexamethylmelamine. The present schedule does not permit adminstration of PMM in a dose not apear to offer an advantage over the p.o. use of the parent compound.

AB - A Phase I study of pentamethylmelamine (PMM) was conducted, administering the drug as a 24-hr i.v. infusion once weekly for 3 weeks. Doses ranged from 80 to 3000 mg/sq m/week. Twenty-six evaluable patients received a total of 30 courses of PMM. The median performance status of the courses of PMM. The median performance status of the patients was 60% (range, 40 to 90%), and the median age wa 58 years (range, 43 to 72 years). The highest tolerated dose was 2000 mg/sq m/ week. Nausea and vomiting were the dose-limiting toxicities; myelosuppression was neither consistent nor severe. One objective response lasting 10 months was noted in a patient with renal cancer. Pharmacokinetic studies using [ring-14C]PMM demonstrated a postinfusion half-life of 1:4C of approximately 12 hr, with the majority of the radiolabel excreted in the urine. PMM was introduced as a parenteral form of hexamethylmelamine. The present schedule does not permit adminstration of PMM in a dose not apear to offer an advantage over the p.o. use of the parent compound.

UR - http://www.scopus.com/inward/record.url?scp=0019461054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019461054&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - 1402

EP - 1406

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 4

ER -